First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study

• Published in: Signal transduction and targeted therapy Vol. 9; no. 1; p. 73
• Main Authors: Chen, Xiaofeng, Xu, Hao, Chen, Xiaobing, Xu, Tongpeng, Tian, Yitong, Wang, Deqiang, Guo, Fen, Wang, Kangxin, Jin, Guangfu, Li, Xiao, Wang, Rong, Li, Fengyuan, Ding, Yongbin, Tang, Jie, Fang, Yueyu, Zhao, Jing, Liu, Liang, Ma, Ling, Meng, Lijuan, Hou, Zhiguo, Zheng, Rongrong, Liu, Yang, Guan, Ni, Zhang, Bei, Tong, Shuang, Chen, Shiqing, Li, Xing, Shu, Yongqian
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 25-03-2024; Nature Publishing Group
• Subjects: 692/4028/67/1504; 692/4028/67/580; Adenocarcinoma; Antibodies, Monoclonal, Humanized; Cancer Research; Cell Biology; Chemotherapy; Gastric cancer; Humans; Immune Checkpoint Inhibitors - therapeutic use; Internal Medicine; Medical prognosis; Medicine; Medicine & Public Health; Oncology; Oxaliplatin; Pathology; Patients; PD-1 protein; Pyridines; Stomach Neoplasms - drug therapy; Stomach Neoplasms - pathology; Surgery; Survival; Vascular Endothelial Growth Factor Receptor-2; Vascular endothelial growth factor receptors
• ISSN: 2059-3635; 2095-9907; 2059-3635
• DOI: 10.1038/s41392-024-01773-9

Patients with advanced gastric cancer typically face a grim prognosis. This phase 1a (dose escalation) and phase 1b (dose expansion) study investigated safety and efficacy of first-line camrelizumab plus apatinib and chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma. The primary endpoints included maximum tolerated dose (MTD) in phase 1a and objective response rate (ORR) across phase 1a and 1b. Phase 1a tested three dose regimens of camrelizumab, apatinib, oxaliplatin, and S-1. Dose regimen 1: camrelizumab 200 mg on day 1, apatinib 250 mg every other day, oxaliplatin 100 mg/m² on day 1, and S-1 40 mg twice a day on days 1–14. Dose regimen 2: same as dose regimen 1, but oxaliplatin 130 mg/m². Dose regimen 3: same as dose regimen 2, but apatinib 250 mg daily. Thirty-four patients were included (9 in phase 1a, 25 in phase 1b). No dose-limiting toxicities occurred so no MTD was identified. Dose 3 was set for the recommended phase 2 doses and administered in phase 1b. The confirmed ORR was 76.5% (95% CI 58.8–89.3). The median progression-free survival was 8.4 months (95% CI 5.9-not evaluable [NE]), and the median overall survival (OS) was not mature (11.6-NE). Ten patients underwent surgery after treatment and the multidisciplinary team evaluation. Among 24 patients without surgery, the median OS was 19.6 months (7.8-NE). Eighteen patients (52.9%) developed grade ≥ 3 treatment-emergent adverse events. Camrelizumab plus apatinib and chemotherapy showed favorable clinical outcomes and manageable safety for untreated advanced gastric cancer (ChiCTR2000034109).